New Treatment Approaches for Older Adults with Multiple Myeloma.

about

Multiple myeloma in the older adult: better prospects, more challenges.The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution.

P2860

Q34031129-C219653D-D14A-47A3-BA6A-DF9CFAA9958C Q36706899-E14DC23C-1AC4-4EF3-80B9-6256BF6E7366

P2860

New Treatment Approaches for Older Adults with Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q38048281

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

New Treatment Approaches for Older Adults with Multiple Myeloma.

@en

type

Item

label

New Treatment Approaches for Older Adults with Multiple Myeloma.

@en

prefLabel

New Treatment Approaches for Older Adults with Multiple Myeloma.

@en

P1476

New Treatment Approaches for Older Adults with Multiple Myeloma.

@en

P2093

Arti Hurria

http://www.w3.org/2001/XMLSchema#string

Bruno C Medeiros

http://www.w3.org/2001/XMLSchema#string

Ravi Vij

http://www.w3.org/2001/XMLSchema#string

Tanya M Wildes

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.

P304

279-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JGO.2012.02.001

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stephen H Petersdorf

P577

2012-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23024730

http://www.w3.org/2001/XMLSchema#string

P932

3458649

http://www.w3.org/2001/XMLSchema#string

New Treatment Approaches for Older Adults with Multiple Myeloma.

about

P2860

P2860

New Treatment Approaches for Older Adults with Multiple Myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932